91476-82-3

Basic information

• Product Name: 5,6,7,8-Tetrahydro-imidazo[1,2-a]pyrazine-2-carboxylic acid ethyl ester
• Synonyms: 5,6,7,8-TETRAHYDRO-IMIDAZO[1,2-A]PYRAZINE-2-CARBOXYLIC ACID ETHYL ESTER;IMidazo[1,2-a]pyrazine-2-carboxylic acid, 5,6,7,8-tetrahydro-, ethyl ester;ethyl 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylate HCl
• CAS NO: 91476-82-3
• Molecular Formula: C₉H₁₃N₃O₂
• Molecular Weight: 195.22
• Mol File: 91476-82-3.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 394.02 °C at 760 mmHg
• Flash Point: 192.097 °C
• Appearance: /
• Density: 1.36 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 5,6,7,8-Tetrahydro-imidazo[1,2-a]pyrazine-2-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6,7,8-Tetrahydro-imidazo[1,2-a]pyrazine-2-carboxylic acid ethyl ester(91476-82-3)
• EPA Substance Registry System: 5,6,7,8-Tetrahydro-imidazo[1,2-a]pyrazine-2-carboxylic acid ethyl ester(91476-82-3)

Safety Data

• Hazardous Substances Data: 91476-82-3(Hazardous Substances Data)

Usage

General Description

5,6,7,8-Tetrahydro-imidazo[1,2-a]pyrazine-2-carboxylic acid ethyl ester is a chemical compound with the formula C11H16N2O2. It is an ethyl ester derivative of imidazo[1,2-a]pyrazine-2-carboxylic acid that is commonly used in the synthesis of pharmaceuticals and other organic compounds. 5,6,7,8-Tetrahydro-imidazo[1,2-a]pyrazine-2-carboxylic acid ethyl ester has been studied for its potential use as a building block for the development of new drugs and as a precursor for the synthesis of various heterocyclic compounds. Its structure and reactivity make it a versatile starting material for the preparation of a range of biologically active molecules. Furthermore, its unique properties and potential applications make it an important compound in the field of medicinal chemistry and drug development.

InChI:InChI=1/C9H13N3O2/c1-2-14-9(13)7-6-12-4-3-10-5-8(12)11-7/h6,10H,2-5H2,1H3

Upstream product

• 1053656-22-6 7-(tert-butyl) 2-ethyl 5,6-dihydroimidazo[1,2-a]pyrazine-2,7(8H)-dicarboxylate 
• 92234-23-6 ethyl 3-bromo-2-hydroxy propionate 
• 70-23-5 ethyl Bromopyruvate 
• 77112-52-8 ethyl imidazo[1,2-a]pyrazine-2-carboxylate 

Downstream Products

• 1053656-22-6 7-(tert-butyl) 2-ethyl 5,6-dihydroimidazo[1,2-a]pyrazine-2,7(8H)-dicarboxylate 
• 723286-62-2 ethyl 7-[(3R)-3-[(tert-butoxycarbonyl)amino]-4-(2,5-difluorophenyl)butanoyl]-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylate 
• 1608503-32-7 7-(5'-chloro-3,5-dimethyl-2,4'-bipyridin-2'-yl)-N-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxamide 
• 1608503-33-8 7-(5'-chloro-3,5-dimethyl-2,4'-bipyridin-2'-yl)-N-(2-fluorophenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxamide 
• 1608503-34-9 C₂₅H₂₂ClFN₆O 
• 1608503-35-0 7-(5'-chloro-3,5-dimethyl-2,4'-bipyridin-2'-yl)-N-(4-fluorophenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxamide 
• 1608503-36-1 C₂₅H₂₁ClF₂N₆O 
• 1608503-42-9 phenyl 7-(5'-chloro-3,5-dimethyl-2,4'-bipyridin-2'-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylate 
• 623564-19-2 7-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylic acid ethyl ester 
• 1174069-07-8 ethyl 7-(tert-butoxycarbonyl)-3-chloro-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylate 
• 1575607-74-7 (2R,3R)-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-3-(2-(ethoxycarbonyl)-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)butan-2-ol 
• 1338562-13-2 C₁₅H₂₂N₄O₃ 
• 1338563-42-0 ethyl 7-(1-methylcyclohexanecarbonyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylate 

Relevant articles and documents

ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF

The invention relates to a ROCK inhibitor represented by formula (I), its preparation method and its use. The ROCK inhibitor has excellent ROCK inhibition activity, in particular good selective inhibition on ROCK2 kinase, has good safety and metabolic stability, and has high bioavailability. The process of preparing the ROCK inhibitor is simple, and the ROCK inhibitor is easy to purify, and therefore offers good prospects for application.

HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS

The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like.

Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility

Triazoles with fused-heterocycle nuclei were designed and evaluated for their in vitro activity on the basis of the binding mode of albaconazole using molecular docking, along with SAR of antifungal triazoles. Tetrahydro-[1,2,4] triazolo[1,5-a]pyrazine and tetrahydro-thiazolo[5,4-c]pyridine nuclei were preferable to the other four fused-heterocycle nuclei investigated. Potent in vitro activity, broad spectrum and better water solubility were attained when triazoles containing nitrogen aromatic heterocycles were attached to these two nuclei. The most potent compounds 27aa and 45x, with low hERG inhibition and hepatocyte toxicity, both exhibited excellent activity against Candida, Cryptococcus, and Aspergillus spp., as well as selected fluconazole-resistant strains. A high water-soluble compound 58 (the disulfate salt of 45x) displayed unsatisfactory in vivo activity because of its poor PK profiles. Mice infected with C.alb. SC5314 and C.alb. 103 (fluconazole-resistant strain) and administered with 27aa displayed significantly improved survival rates. 27aa also showed favorable pharmacokinetic (PK) profiles.